The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results.
K. Boyd
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
G. Morgan
Honoraria - Celgene; Johnson & Johnson; Merck; Novartis
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
F. Davies
Honoraria - Celgene; Novartis
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
P. Wu
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
W. Gregory
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
S. E. Bell
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
A. Szubert
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
N. Navarro Coy
No relevant relationships to disclose
M. Drayson
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
R. G. Owen
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
S. Feyler
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
J. Ashcroft
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
F. Ross
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
J. Byrne
Consultant or Advisory Role - Novartis
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
H. Roddie
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
C. Rudin
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
G. Cook
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
G. H. Jackson
Honoraria - Ortho Biotech
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech
J. A. Child
Research Funding - Bayer Schering Pharma; Celgene; Chugai Pharma; Novartis; Ortho Biotech